Kathryn Romano Biography and Net Worth

CAO of Krystal Biotech

Kathryn Romano was named Chief Accounting Officer in February 2020. Kathryn most recently held the position of Corporate Controller at CNX Resources Corporation. Prior to joining CNX, Kathryn was the Corporate Controller of Rice Energy from January 2013 until the company was acquired by EQT in November 2017, staying on to assist the company through the transition until March 2018. Prior to joining Rice Energy, Kathryn worked in a variety of accounting and auditing roles at Black Box Corporation and Deloitte. Kathryn is a Certified Public Accountant and holds a Bachelor of Science in Accounting from Penn State University.

What is Kathryn Romano's net worth?: The estimated net worth of Kathryn Romano is at least $2.13 million as of February 28th, 2024. Ms. Romano owns 12,936 shares of Krystal Biotech stock worth more than $2,132,241 as of December 21st. This net worth evaluation does not reflect any other investments that Ms. Romano may own. Additionally, Ms. Romano receives a salary of $614,870.00 as CAO at Krystal Biotech. Learn More about Kathryn Romano's net worth.
How old is Kathryn Romano?: Ms. Romano is currently 42 years old. There are 2 older executives and no younger executives at Krystal Biotech. The oldest executive at Krystal Biotech is Mr. Krish S. Krishnan M.B.A., M.S., Founder, Chairman, President & CEO, who is 59 years old. Learn More on Kathryn Romano's age.
What is Kathryn Romano's salary?: As the CAO of Krystal Biotech, Inc., Ms. Romano earns $614,870.00 per year. There are 2 executives that earn more than Ms. Romano. The highest earning executive at Krystal Biotech is Mr. Krish S. Krishnan M.B.A., M.S., Founder, Chairman, President & CEO, who commands a salary of $1,320,000.00 per year. Learn More on Kathryn Romano's salary.
How do I contact Kathryn Romano?: The corporate mailing address for Ms. Romano and other Krystal Biotech executives is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. Krystal Biotech can also be reached via phone at (412) 586-5830 and via email at [email protected]. Learn More on Kathryn Romano's contact information.
Has Kathryn Romano been buying or selling shares of Krystal Biotech?: Kathryn Romano has not been actively trading shares of Krystal Biotech in the last ninety days. Most recently, Kathryn Romano sold 5,000 shares of the business's stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $165.88, for a transaction totalling $829,400.00. Following the completion of the sale, the chief accounting officer now directly owns 12,936 shares of the company's stock, valued at $2,145,823.68. Learn More on Kathryn Romano's trading history.
Who are Krystal Biotech's active insiders?: Krystal Biotech's insider roster includes Julian Gangolli (Director), Daniel Janney (Director), Krish Krishnan (CEO), Suma Krishnan (COO), Kathryn Romano (CAO), and Dino Rossi (Director). Learn More on Krystal Biotech's active insiders.
Are insiders buying or selling shares of Krystal Biotech?: In the last year, insiders at the sold shares 8 times. They sold a total of 135,587 shares worth more than $23,275,691.17. The most recent insider tranaction occured on December, 13th when insider Suma Krishnan sold 25,000 shares worth more than $4,119,500.00. Insiders at Krystal Biotech own 14.1% of the company. Learn More about insider trades at Krystal Biotech.
Information on this page was last updated on 12/13/2024.

Kathryn Romano Insider Trading History at Krystal Biotech

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/28/2024	Sell	5,000	$165.88	$829,400.00	12,936
2/26/2024	Sell	8,087	$136.91	$1,107,191.17	12,556
1/22/2024	Sell	2,500	$130.00	$325,000.00	12,556
5/22/2023	Sell	25,000	$109.04	$2,726,000.00	12,556
5/19/2023	Sell	28,428	$95.05	$2,702,081.40	12,556

Kathryn Romano Buying and Selling Activity at Krystal Biotech

Krystal Biotech Company Overview

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Today's Range

Now: $164.83

$159.20

$165.98

50 Day Range

MA: $180.18

$156.64

$199.61

2 Week Range

Now: $164.83

$107.50

$219.34

Volume

892,241 shs

Average Volume

325,570 shs

Market Capitalization

$4.74 billion

P/E Ratio

93.12

Dividend Yield

N/A

Beta

0.8

Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong

From Brownstone Research | Ad

Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.

Click here to watch this demo and decide for yourself.

Kathryn Romano Biography and Net Worth

What is Kathryn Romano's net worth?

How old is Kathryn Romano?

What is Kathryn Romano's salary?

How do I contact Kathryn Romano?

Has Kathryn Romano been buying or selling shares of Krystal Biotech?

Who are Krystal Biotech's active insiders?

Are insiders buying or selling shares of Krystal Biotech?